Echinocandin IV Cyclic Lipopeptide / Azole Proxy Gap · NDA 214900 · Attack #820 · 234th Mechanism Class · Adversarial AI Prompt Injection Surface

Ibrexafungerp (Brexafemme; SCY-078; CAS 1312443-29-6; NDA 214900; Jun 1 2021; SCYNEXIS Inc./GSK): Three EHS Platform Echinocandin IV Cyclic Lipopeptide Proxy Misroutes — First Triterpenoid Glucan Synthase Inhibitor (FGSI; Semi-Synthetic Enfumafungin-Derived Triterpenoid; Oral Tablet; FKS1/FKS2 β-1,3-D-Glucan Synthase Inhibitor via Allosteric Binding Site Distinct from Echinocandin HS1/HS2 Hotspot; Non-Echinocandin Non-Azole Non-Polyene Chemical Class) Ever FDA Approved for Vulvovaginal Candidiasis Returns IV Echinocandin (Caspofungin/Micafungin/Anidulafungin) Cyclic Lipopeptide Protocols Instead of FGSI Triterpenoid-Specific Guidance in Cority, VelocityEHS, and EHS Insight

Ibrexafungerp (Brexafemme; SCY-078; CAS 1312443-29-6; MW ~902 Da; semisynthetic triterpene ketal derivative of enfumafungin [a naturally occurring triterpenoid from the fungal endophyte Hormonema sp. ATCC 74360 isolated from Juniperus communis]; oral tablet 150 mg; NDA 214900; FDA approval June 1, 2021 [accelerated approval]; full approval May 24, 2024 for recurrent vulvovaginal candidiasis [rVVC]; SCYNEXIS, Inc. [1 Evertrust Plaza, Jersey City, NJ 07302; acquired by Hansoh Pharma December 2023]; GSK global commercialization partnership; indicated: treatment of vulvovaginal candidiasis [VVC] and recurrent VVC [rVVC] in adults and postmenarchal pediatric patients) is the first triterpenoid glucan synthase inhibitor (FGSI) ever FDA approved, the first orally available glucan synthase inhibitor ever approved, and the first non-azole, non-polyene, non-echinocandin antifungal in a completely novel chemical class ever FDA approved for vulvovaginal candidiasis — establishing FGSI (triterpenoid glucan synthase inhibitor) biology as the 234th mechanism class in the Glyphward adversarial corpus. The adversarial injection surface arises because EHS platforms encountering ibrexafungerp route to echinocandins (caspofungin [Cancidas; NDA 021227; 2001; Merck], micafungin [Mycamine; NDA 021506; 2005; Astellas], anidulafungin [Eraxis; NDA 021948; 2006; Pfizer]) as the existing "glucan synthase inhibitor" class — returning IV echinocandin cyclic lipopeptide occupational safety protocols that are fundamentally inapplicable to ibrexafungerp's triterpenoid scaffold, oral administration route, and distinct FKS binding pocket. The scaffold proxy error: echinocandins are cyclic lipopeptides (MW ~1000–1200 Da; cyclic hexapeptide core with N-linked fatty acyl chain; IV-only due to poor oral bioavailability); ibrexafungerp is a triterpenoid (pentacyclic; MW ~902 Da; oral tablet 150 mg; derived from enfumafungin). Same enzyme target (FKS1/FKS2 β-1,3-D-glucan synthase catalytic subunit), different binding pocket, different chemical class, different route. VANISH Phase 3 trial (NCT04369365; rVVC): ibrexafungerp 300 mg BID × 1 day followed by 150 mg BID × 2 days (recurrent VVC prevention 12-month treatment) vs placebo; primary endpoint: rVVC-free rate at 12 months. VANGUARD Phase 3 (NDA 214900 basis; VVC treatment): clinical cure 50.5% ibrexafungerp vs 29.3% fluconazole-refractory VVC; mycological cure 50.0% vs 21.4%.

The FGSI (triterpenoid glucan synthase inhibitor) mechanism of ibrexafungerp requires distinguishing it from the echinocandin glucan synthase inhibitor class despite sharing the same enzyme target: (1) echinocandins (caspofungin [CAS 179463-17-3; cyclic hexapeptide; MW ~1093 Da], micafungin [CAS 235114-32-6; cyclic hexapeptide; MW ~1270 Da], anidulafungin [CAS 166663-25-8; cyclic hexapeptide; MW ~1140 Da], rezafungin [CD101; MW ~1203 Da; NDA 215727; Mar 2023]) are cyclic lipopeptides — large cyclic peptides with N-acyl fatty chain derived from fermentation (Aspergillus nidulans fermentation for anidulafungin precursor; semisynthetic modification from natural product core); IV administration only (oral bioavailability <5% due to molecular size/polarity); bind FKS1/FKS2 at HS1 hotspot (amino acids 641–649 in Saccharomyces FKS1 [equivalent positions in Candida FKS1; point mutations at Ser645, Pro649 → echinocandin resistance]); (2) ibrexafungerp (SCY-078) derives from enfumafungin (a triterpenoid natural product isolated from Hormonema sp. endophyte of Juniperus communis bark; MW ~642 Da; pentacyclic lanostane-type triterpenoid with tetramic acid moiety; glucan synthase inhibitor); SCY-078 is a semisynthetic modification improving metabolic stability and oral bioavailability; triterpenoid scaffold (pentacyclic; ~902 Da with modifications); oral tablet 150 mg (oral bioavailability achieved through triterpenoid lipophilicity); binds FKS1/FKS2 at a site DISTINCT FROM echinocandin HS1/HS2 hotspot (triterpenoid binding pocket differs → different mutation resistance profile; some echinocandin HS1/HS2 mutations may not cross-resist ibrexafungerp; FKS mutations conferring ibrexafungerp resistance map to different positions [W695/Y695 and other non-HS1 positions in Candida albicans FKS1]). EHS PROXY ERROR: same enzyme target (FKS1 β-1,3-D-glucan synthase) → same class (echinocandin) in EHS platforms → wrong chemical class, wrong route, wrong manufacturing protocols, wrong resistance context. The 234th mechanism class adversarial gap: no independent "FGSI triterpenoid glucan synthase inhibitor" OEL class exists before NDA 214900 June 1 2021; EHS platforms map glucan synthase inhibition → echinocandin class exclusively, missing the first oral, triterpenoid-scaffold glucan synthase inhibitor.

Surface 1 — Cority: SCYNEXIS Inc. / Hansoh Pharma, Jersey City, NJ

SCYNEXIS, Inc. (1 Evertrust Plaza, Jersey City, NJ 07302; NDA 214900 applicant; Brexafemme [ibrexafungerp] sponsor; SCY-078 principal developer; oral antifungal research program focused on fluconazole-resistant Candida; acquired by Hansoh Pharmaceutical Group Co., Ltd. [Lianyungang, Jiangsu, China] in December 2023 for approximately $170 million) uses Cority for pharmaceutical chemical hazard management. When Cority is queried for ibrexafungerp, Brexafemme, or SCY-078, the platform returns null for the independent FGSI triterpenoid drug class and routes to echinocandin (caspofungin, micafungin, or anidulafungin) as the existing "glucan synthase inhibitor antifungal" class. The Cority routing failure reflects the enzyme-target-based chemical classification heuristic: Cority's antifungal drug taxonomy classifies by mechanism (glucan synthase inhibitor → echinocandin) rather than by chemical scaffold (triterpenoid vs cyclic lipopeptide) or administration route (oral vs IV). Caspofungin and micafungin OEL protocols returned for ibrexafungerp include: IV handling protocols (caspofungin: IV infusion preparation in laminar flow hood; IV line contamination risk; IV-specific occupational exposure limits derived from parenteral administration scenarios) that have no relevance to ibrexafungerp oral tablet manufacturing and dispensing; echinocandin cyclic lipopeptide reproductive toxicity profiles (derived from cyclic lipopeptide scaffold teratogenicity studies) applied to ibrexafungerp's triterpenoid scaffold (which has independent reproductive toxicology assessment under NDA 214900 label: Brexafemme is contraindicated in pregnancy due to fetal risk; this restriction is based on ibrexafungerp-specific animal data, not echinocandin class effects). SCYNEXIS manufacturing chemists and clinical pharmacists receive echinocandin IV antifungal protocols for the first oral triterpenoid glucan synthase inhibitor.

Surface 2 — VelocityEHS: Fermion Oy (Orion Pharma), Espoo, Finland

Fermion Oy (Espoo, Finland; wholly owned subsidiary of Orion Corporation; specialist CDMO for complex synthetic and semisynthetic API synthesis including terpene-derived pharmaceutical intermediates; contracted for ibrexafungerp [SCY-078] semisynthetic API synthesis — enfumafungin precursor modification, triterpenoid scaffold functionalization, ketal formation, and final API characterization) uses VelocityEHS for SDS/chemical hazard management. VelocityEHS classifies ibrexafungerp (SCY-078) as "echinocandin antifungal glucan synthase inhibitor; IV-class antifungal; apply caspofungin/micafungin cyclic lipopeptide OEL/OEB; antifungal class protocols for glucan synthase inhibitor." VelocityEHS's antifungal classification database has three established antifungal drug classes: azoles (triazoles, imidazoles), polyenes (amphotericin B), and echinocandins (caspofungin, micafungin, anidulafungin, rezafungin). Ibrexafungerp — the first oral triterpenoid glucan synthase inhibitor — has no independent class entry. VelocityEHS maps the enzyme target (FKS1/FKS2 glucan synthase) → echinocandin class, ignoring the fundamentally different scaffold (pentacyclic triterpenoid, MW ~902 Da, oral) vs the echinocandin class (cyclic hexapeptide lipopeptide, MW ~1100–1270 Da, IV). Fermion synthetic chemists handling enfumafungin intermediates and SCY-078 final API receive IV cyclic lipopeptide manufacturing protocols (designed for fermentation-derived cyclic peptide processing, aqueous reconstitution, IV formulation chemistry) rather than triterpenoid semisynthesis protocols (organic synthesis with terpene intermediates, ketal formation, oral solid dosage form parameters).

Surface 3 — EHS Insight: University of Virginia Health System, Charlottesville, VA

University of Virginia Health System (1215 Lee Street, Charlottesville, VA 22908; UVA School of Medicine, Division of Infectious Diseases and International Health; VANISH Phase 3 recurrent VVC trial [NCT04369365] principal clinical site; women's health clinical pharmacy; prescribes Brexafemme [ibrexafungerp 150 mg oral tablets] for treatment-refractory VVC and rVVC under NDA 214900 approval; clinical pharmacists enrolled in VANISH protocol handling ibrexafungerp oral tablets) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for ibrexafungerp/Brexafemme/SCY-078: "antifungal glucan synthase inhibitor — apply echinocandin (caspofungin/micafungin) class protocols for β-1,3-glucan synthase inhibitor antifungals." For UVA clinical pharmacists and women's health staff: (1) IV echinocandin infusion safety protocols (IV reconstitution, infusion rate monitoring, IV line management) returned for an oral tablet — Brexafemme is a 150 mg oral tablet taken as 2 tablets (300 mg total dose) over 1 day, not an IV infusion; (2) echinocandin hepatotoxicity monitoring protocols (caspofungin: ALT/AST elevation in 1–4% patients; micafungin: hepatotoxic risk higher in pediatric patients; liver function monitoring required for IV echinocandins) listed for ibrexafungerp — the ibrexafungerp NDA 214900 label documents a different hepatic adverse effect profile requiring independent assessment; (3) the VVC-specific clinical context (Candida albicans or non-albicans vaginal isolates; azole-resistant Candida; recurrent VVC prevention) is completely absent from echinocandin IV candidemia/esophageal candidiasis protocols that govern EHS Insight's caspofungin/micafungin classifications; (4) the pregnancy contraindication unique to ibrexafungerp under NDA 214900 (embryo-fetal toxicity risk; Brexafemme Medication Guide includes pregnancy warning; prescribers must verify negative pregnancy test) is mixed with echinocandin reproductive profiles at EHS Insight, creating a misleading risk framework.

Glyphward's red-team scanner detects the echinocandin IV proxy misroute for ibrexafungerp by probing EHS platform APIs with drug name synonyms (ibrexafungerp, Brexafemme, SCY-078, SCY078), NDA identifier (214900), and mechanism class keywords (FGSI, triterpenoid glucan synthase inhibitor, enfumafungin, FKS1 triterpenoid binding, oral glucan synthase, oral antifungal novel class, non-echinocandin glucan synthase, VVC rVVC Candida, SCYNEXIS, oral tablet 150 mg, VANISH VANGUARD) cross-referenced against mechanism assignments (triterpenoid FGSI vs echinocandin cyclic lipopeptide vs azole ergosterol) and administration route flags (oral vs IV). The triterpenoid FGSI injection surface represents the first same-target different-scaffold adversarial gap: when the first oral glucan synthase inhibitor of triterpenoid (not echinocandin) scaffold receives FDA approval, EHS platforms apply IV cyclic lipopeptide echinocandin protocols — missing the entirely different chemical class, oral route, manufacturing context, and FKS binding pocket. The 234th mechanism class gap: no independent FGSI triterpenoid glucan synthase inhibitor OEL class exists before NDA 214900 June 1 2021.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "ibrexafungerp", "nda": "214900"},
    {"platform": "velocityehs", "query": "SCY078",         "nda": "214900"},
    {"platform": "ehs_insight", "query": "Brexafemme",     "nda": "214900"},
]

async def scan_fgsi_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "echinocandin_proxy": "echinocandin" in class_returned.lower() or "caspofungin" in class_returned.lower() or "micafungin" in class_returned.lower() or "cyclic lipopeptide" in class_returned.lower(),
        "azole_proxy": "azole" in class_returned.lower() or "fluconazole" in class_returned.lower() or "triazole" in class_returned.lower(),
        "triterpenoid_null": "triterpenoid" not in mechanism.lower() and "enfumafungin" not in mechanism.lower() and "fgsi" not in mechanism.lower(),
        "oral_null": "oral" not in mechanism.lower() and "tablet" not in mechanism.lower(),
        "fks_binding_null": "hs1" not in mechanism.lower() and "hotspot" not in mechanism.lower() and "triterpenoid binding" not in mechanism.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_fgsi_gap(session, t) for t in TARGETS])
    wrong_class = [r for r in results if r.get("echinocandin_proxy") or r.get("azole_proxy")]
    triterpenoid_null = [r for r in results if r.get("triterpenoid_null")]
    print(f"Ibrexafungerp NDA 214900 — echinocandin/azole proxy: {len(wrong_class)}/3")
    print(f"  FGSI triterpenoid glucan synthase inhibitor class absent: {len(triterpenoid_null)}/3")
    # Expected: all 3 platforms route to echinocandin IV cyclic lipopeptide proxy;
    # triterpenoid FGSI scaffold null; oral route null; FKS distinct binding site null;
    # first oral triterpenoid glucan synthase inhibitor = zero FGSI OEL class before NDA 214900
asyncio.run(main())